Management of Hyperphosphatemia Following Hemodialysis Initiation in CKD

Introduction to Hyperphosphatemia Management

The National Kidney Foundation recommends maintaining serum phosphorus between 3.5-5.5 mg/dL in Stage 5 CKD patients on dialysis 1, 3
Treatment decisions must be based on serial measurements of phosphate, calcium, and PTH considered together, not single values in isolation, as suggested by the American College of Physicians 2, 4
High phosphate levels are robustly associated with increased mortality and cardiovascular morbidity in dialysis patients, according to the American Heart Association 5, 6

Restrict dietary phosphorus to 800-1,000 mg/day, adjusted for protein needs, as recommended by the Academy of Nutrition and Dietetics 7, 1, 8

When serum phosphorus remains >5.5 mg/dL despite dietary restriction, initiate phosphate binders, as suggested by the American College of Physicians 1, 2
Switch to or add non-calcium-based binders when hypercalcemia develops, arterial calcification is present, adynamic bone disease exists, or PTH levels are persistently low, according to the Kidney Disease: Improving Global Outcomes guidelines 9, 2

Standard thrice-weekly hemodialysis has limited phosphorus removal capacity, as noted by the National Kidney Foundation 5, 6
Consider extended dialysis time (>24 hours/week over ≥3 treatments) for refractory hyperphosphatemia, as recommended by the American Society of Nephrology 5, 6

Monitor serum phosphorus monthly following initiation of dietary restriction or treatment changes, as suggested by the American College of Physicians 7, 8
Avoid hypercalcemia, as excessive calcium-based binders increase cardiovascular calcification risk and mortality, according to the American Heart Association 2, 10
Do not treat normal phosphorus levels with binders in non-dialysis CKD, as a recent trial showed increased coronary calcification with binder use in CKD G3b-G4 patients with normal phosphorus, as noted by the American College of Physicians 10, 4

Phosphate retention begins early in CKD (Stage 1-2) and drives secondary hyperparathyroidism, even when serum phosphorus remains normal, as explained by the National Kidney Foundation 7, 1
By Stage 4-5 CKD (GFR <30 mL/min/1.73 m²), overt hyperphosphatemia develops, according to the Kidney Disease: Improving Global Outcomes guidelines 7, 1
In dialysis patients, fewer than 30% maintain phosphorus in target range with current therapies, as noted by the American Society of Nephrology 1, 3